Replimune Group (REPL)
(Delayed Data from NSDQ)
$9.86 USD
+0.13 (1.34%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $9.85 -0.01 (-0.10%) 7:38 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Replimune Group, Inc. (REPL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$14.78 | $17.00 | $12.00 | 51.90% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Replimune Group, Inc. comes to $14.78. The forecasts range from a low of $12.00 to a high of $17.00. The average price target represents an increase of 51.9% from the last closing price of $9.73.
Analyst Price Targets (9 )
Broker Rating
Replimune Group, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, nine are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/REPL.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 9 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/7/2024 | H.C. Wainwright & Co. | Robert Burns | Strong Buy | Strong Buy |
5/21/2024 | Piper Sandler | Allison M Bratzel | Strong Buy | Strong Buy |
5/17/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/16/2024 | Wedbush Securities | Robert Driscoll | Strong Buy | Strong Buy |
5/16/2024 | SVB Securities | Jonathan W Chang | Strong Buy | Strong Buy |
1/9/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
12/6/2023 | BTIG | Kaveri Pohlman | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 9 |
Average Target Price | $14.78 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 72 of 253 |
Current Quarter EPS Est: | -0.79 |